长效注射卡博特韦/利匹韦林居家与门诊给药的比较
本研究为美国南卡罗来纳医科大学感染病门诊开展的非随机观察性研究,2021年8月至2022年12月纳入33例接受长效注射卡博特韦/利匹韦林(LA CAB/RPV)治疗者,在门诊完成首次注射后由受试者选择后续12个月在门诊或居家接受注射。结果显示两组安全性与有效性无差异,注射部位疼痛/酸痛常见(占52%的注射)但组间无差异,两组治疗满意度均高,所有受试者研究结束时病毒学抑制且保留在照护中。
要点
- 居家与门诊接受LA CAB/RPV注射的安全性和有效性无差异。
- 注射部位疼痛/酸痛常见(52%的注射),组间无差异。
- 两组均报告高治疗满意度,研究结束时全部病毒学抑制并保留在照护中。
核心结论
- 由医疗保健人员在居家给予LA CAB/RPV与门诊给药相比安全性、有效性相当,且参与者满意度高。
研究设计与样本
- 南卡罗来纳医科大学感染病门诊开展的非随机观察性研究,2021年8月至2022年12月纳入33例接受LA CAB/RPV治疗者;门诊完成首次注射后,受试者选择后续12个月在门诊或居家接受每次注射。
主要发现
- 33例入组者以黑人(64%)、男性(73%)为主,中位年龄46岁。
- 3例因过敏(n=1)、病毒学抑制丧失(n=1)、就诊依从性(n=1)担忧停用LA CAB/RPV并转为口服抗逆转录病毒治疗。
- 主要门诊接受治疗者18例,主要居家接受治疗者15例。
- 注射部位疼痛/酸痛常见(52%的注射),但组间无差异;两组安全性和有效性无差异,均报告高治疗满意度。
- 研究结束时所有受试者均病毒学抑制并保留在照护中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The need for frequent travel to a clinic could impair access to injectable antiretroviral therapy for persons with human immunodeficiency virus type 1 (HIV-1) infection. We hypothesized that allowing persons receiving treatment with long-acting injectable cabotegravir plus rilpivirine (LA CAB/RPV) to receive and store the medication in their own refrigerator prior to in-home administration by a healthcare provider would be as safe and effective as receiving treatment in a clinic. METHODS: Persons prescribed LA CAB/RPV in the Infectious Diseases clinic at the Medical University of South Carolina were offered enrollment in this non-randomized, observational study between August 2021 and December 2022. After in-clinic receipt of the initial LA CAB/RPV injection, participants chose to receive each subsequent injection over the following 12-months either in clinic or at home. RESULTS: The 33 enrolled participants were primarily Black (64%), male (73%), and had a median age of 46. Three participants stopped LA CAB/RPV and transitioned to oral antiretroviral therapy due to allergy (n = 1), loss of virologic suppression (n = 1), and visit adherence (n = 1) concerns. A comparable number of participants received treatment primarily in clinic (n = 18) relative to at home (n = 15). Injection site pain/soreness was common (52% of injections) but did not differ between groups. There were no differences in safety or efficacy between groups and both groups reported high treatment satisfaction. All participants were virologically suppressed and retained in care at the end of the study. CONCLUSIONS: At-home administration of LA CAB/RPV by a healthcare provider was comparably safe, effective, and associated with high participant satisfaction relative to in-clinic administration.
引用
- Kirk SE, Young C, Berry H, et al. Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine. Clin Infect Dis. 2025. PMID: 39377751. doi:10.1093/cid/ciae472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。